THANK YOU. I saw that where they said: "Marker developed MT-601, a new product targeting six tumor-associated antigens (PRAME, NY-ESO-1, Survivin, MAGE-A4, SSX2, WT1) highly expressed in pancreatic cancer."
Personally I think that's great. a NEW product. It just makes so much more sense.
I ponder where we would be had Alex Trebek tried MRKR .... and he was still alive today.
I think we would be discussing when we break above $20 a share, instead of $1 a share.
God I hope we are all right, not just for investors, but for Patients ...
for hopefully, several different cancers.
News 
Market Data 
Discover 
